Zetagen Therapeutics Secures $9.79 Million Series B Funding
Summary
We have a robust and diverse pipeline of oncologic treatments in various stages of development and this funding will accelerate each asset, as well as build out the necessary expertise required to bring these important therapies to fruition.The Company has been issued two Breakthrough Device Designations from the U.S. Food and Drug Administration (FDA) for ZetaMet and ZetaFuse\xae and issued multiple patents from the U.S. Patent and Trademark Office (USPTO). In addition to ZetaMet, the funding will propel the development of ZetaMAST for the treatment of metastatic lesions to soft tissue organs, as well as other oncologic and osteologic pipeline assets. We believe the development of ZetaMet and ZetaMAST as well as the Companys other clinical programs have the potential to make a significant contribution to the treatment of late-stage cancers and more importantly, to the lives of those living with late-stage cancer.Participating in the financing round were New York Ventures and Consolidated Capital Investments, LLC, and an amalgam of private investors.ZetaMet is a synthetic, small-molecule, inductive biologic technology being developed to target and resolve metastatic bone lesions while inhibiting future tumor growth and regenerating bone. ZetaMAST is a first-of-its kind formulation specifically designed for intra-tumoral injection in soft tissue organs like the liver, lung and or brain. The companys pipeline encompasses further oncological solutions, targeting metastatic prostate cancer and addressing Skeletal Related Events (SREs), such as Z-Pros and ZetaMet Flowable, alongside supplementary treatments for osteological conditions like ZetaFuse and ZetaBase\xae.